OVA1® is an FDA-cleared blood test with unparalleled ability to detect ovarian cancer in women who are planned for surgery for a pelvic mass.  OVA1, Vermillion’s first-generation Multivariate Index Assay (MIA), evaluates the levels of five ovarian cancer-associated markers in the blood and utilizes a sophisticated mathematical formula to combine these levels into a single ovarian cancer risk score.  By incorporating multiple markers, OVA1 (MIA) is able to detect more ovarian cancers, including less common forms of cancer, than alternative testing modalities.  Critically, OVA1 (MIA) can detect early stage ovarian cancer which is associated with dramatically better survival rates.  Given OVA1’s superior detection capabilities, a negative OVA1 (MIA) result is accompanied by a 98% likelihood that the woman being tested is in fact disease free.

Overa, a second-generation Multivariate Index Assay (MIA2G) is an FDA-cleared blood test for women with a pelvic mass who are planned for surgery. Overa (MIA2G) maintains the high level of ovarian cancer detection, across rare subtypes and including early stage cancers, afforded by OVA1 (MIA). However, Overa (MIA2G) incorporates different markers and a refined algorithm in order to improve the balance between ovarian cancer detection and healthcare efficiency. Overa (MIA2G) represents a significant improvement in positive predictive value, overall accuracy and a reduction in false positives and unnecessary referrals. With Overa (MIA2G), healthcare providers can feel confident that they are using the best tool for ovarian cancer detection while minimizing the inefficiencies to the healthcare system and patient anxiety associated with false positive results.